Table 1. Patient characteristics and mutational status of CRC explants.
| CRC explant | Primary | Stage | Age at consent | Previous treatment | KRAS | NRAS | PIK3CA | APC | CTNNB1 | BRAF | TP53 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CRC 001 |
Colon |
IV |
69 |
FOLFOX+bevacizumab |
G12D |
WT |
WT |
Mut |
WT |
WT |
WT |
| CRC 006 |
Colon |
IV |
42 |
Capecitabine+ Radiation, FOLFOX+bevacizumab, Irinotecan+cetuximab |
G12D |
WT |
WT |
Mut |
WT |
WT |
WT |
| CRC 007 |
Colon |
II |
47 |
None |
G13D |
WT |
WT |
WT |
Mut |
WT |
Mut |
| CRC 010 |
Rectal |
III |
52 |
None |
WT |
WT |
WT |
WT |
WT |
WT |
Mut |
| CRC 012 |
Rectal |
IV |
56 |
Capecitabine+ Oxaliplatin+bevacizumab |
G12V |
WT |
WT |
WT |
WT |
WT |
WT |
| CRC 020 |
Colon |
IV |
43 |
FOLFOX+bevacizumab |
WT |
G12S, Q61K |
Mut |
Mut |
WT |
WT |
WT |
| CRC 021 |
Rectal |
II |
72 |
None |
G12D |
WT |
WT |
WT |
WT |
WT |
Mut |
| CRC 026 |
Colon |
IV |
48 |
FOLFOX and bevacizumab |
WT |
Q61K |
WT |
Mut |
WT |
WT |
WT |
| CRC 027 |
Colon |
IV |
56 |
None |
G12A |
WT |
WT |
Mut |
WT |
WT |
Mut |
| CRC 034 |
Colon |
IV |
59 |
None |
WT |
WT |
WT |
WT |
WT |
WT |
WT |
| CRC 035 |
Colon |
IV |
44 |
FOLFOX |
G12S |
WT |
WT |
WT |
WT |
WT |
WT |
| CRC 036 |
Rectal |
IV |
42 |
Capecitabine+Radiation, FOLFOX+bevacizumab, Irinotecan+cetuximab |
G12A |
WT |
WT |
Mut |
WT |
WT |
WT |
| CRC 040 |
Rectal |
II |
63 |
None |
G12V |
WT |
Mut |
Mut |
WT |
WT |
WT |
| CRC 042 |
Rectal |
II |
73 |
FOLFIRI+bevacizumab |
G13D |
WT |
WT |
WT |
Mut |
WT |
Mut |
| CRC 052 |
Colon |
II |
51 |
None |
G12V |
WT |
WT |
Mut |
WT |
WT |
WT |
| CRC 065 | Colon | IV | 66 | FOLFIRI, FOLFOX | G12V | WT | WT | Mut | WT | WT | WT |